Investor profile
Illumina Ventures
See how your deck fits this investor's thesis, stage, and ticket size.
Analyse your fitInvestment thesis
Illumina Ventures is the premier genomics and precision health venture firm, investing in early-stage companies to improve human health. Independently managed with a strategic relationship with Illumina (Nasdaq: ILMN), the firm brings depth of knowledge, decades of domain expertise, and strong operating experience to identify and build companies that will transform healthcare. The firm focuses on life science tools, clinical diagnostics, therapeutics platforms, digital health, and other applications of genomics — backing great teams with technology platforms that have broad applicability across multiple market opportunities. Through Illumina Ventures Labs, it accelerates value creation for early-stage genomics start-ups via access to capital, sequencing, mentorship, and fully equipped genomics lab capabilities.
Notable quotes
“Genomics and precision medicine are revolutionizing the healthcare industry. This larger fund enables us to pursue more ambitious projects in the US and Europe while building upon the strategies and core values that have been successful in the past.”
“It's a great time to be investing in genomics. Rapid advances in both sequencing technology and our understanding of the human genome are creating lots of opportunities to build exciting companies. Many of our portfolio companies are pursuing approaches that would not have been practical or even possible five years ago. We like to back great teams with technology platforms that have broad applicability across multiple markets opportunities.”
“Illumina Ventures supports innovative companies that are pursuing breakthrough science, and our partnership with Integrated Biosciences represents an investment in the intersection of healthcare, genomics, and sequencing.”
Recent investments
| Company | Round | Size | Date |
|---|---|---|---|
| Lightcast | Series C | $27m | 2026-04-15 |
| Hepta Bio | Seed | $7m | 2025-11-05 |
| DeepSeq.AI | Seed | — | 2025-12-10 |
| Iambic Therapeutics | Series B | $100m | 2024-06-18 |
| Sonothera | Series B | $125m | 2024-01-01 |
| Twist Bioscience | Series E | — | 2018-01-01 |
| Sherlock Biosciences | Series A | — | 2019-01-01 |
| Alamar Biosciences | Series B | — | 2022-01-01 |
| DNAScript | Series C | — | 2021-01-01 |
| Encoded Therapeutics | Series B | — | 2020-01-01 |
Frequent co-investors
| VC firm | Deals together |
|---|---|
| ARCH Venture Partners | 6 |
| Abingworth | 3 |
| Alexandria Venture Investments | 3 |
| Felicis Ventures | 2 |
| Bpifrance | 2 |
| Nexus Venture Partners | 2 |
Fit check
Is Illumina Ventures a match for your startup?
Upload your deck and get an instant AI-powered fit analysis — see exactly how your startup aligns with this investor's thesis, stage focus, and ticket size.
Analyse your fit